Interpreting whole genome variants
Actionable target selection is a critical drug discovery challenge that requires solving not only the whole genome’s noise and sample size problems, but also interpreting variants outside the exome. Achieving these lead to an expansion of what it means for a target to be genetically-defined.
Drugging the RNA: part I, Why do it?
In part I of a series of posts discussing how to drug RNA, we discuss the three dimensions on which a disease target can be drugged, and how RNA’s dual role as both blueprint and object confers it unique properties that make it a particularly attractive target dimension over protein and DNA.
Welcome to Larry Senour
We are excited to welcome Larry Senour to Genetic Intelligence to help lead business development. Larry has 30 years of healthcare experience in strategy, operations and transaction roles, including 23 years with Merck & Co., Inc. In his last role at Merck he was Managing Director of Healthcare Services & Solutions, a
VIDEO: Experience Genetic Intelligence
Watch the Genetic Intelligence vision. Genetic Intelligence finds truly causal disease targets and designs medicines to fix them. With Genetic Intelligence, you can step into the future of drug discovery. You can take in all of the interconnected parts of your program in full clarity. You can drive better collaboration,
Introduction to David Young: Working to Shift the Genetics Paradigm
Life can be tragic, full of pain, disease, and death. We live in a world surrounded by these horrors that gnaw at the bones of our very existence. But why should we accept it as the default? Can we not ease the suffering of this world? Disease has been caught
An introduction to Andrew Young
I have always been curious about the design of truly impactful products and software, and how they can change the dynamics of a market. These passions led me to pursue mechanical engineering at the Massachusetts Institute of Technology (MIT) with a focus on entrepreneurship. At MIT where I was also
How people of the future will see today's medicine
The past world was gripped with apocalyptic fears where most things were explained with imaginative tales of demons and witches. In this backdrop, terrifying outbreaks killed millions. People of the future will look back on our time with the same incredulity we look at these past times.
Solving the rate-limiting steps of drug discovery
Drug development is arduous and lengthy. That difficulty is reflected in the price of medicine as high drug prices. But the story would be very different and relief brought to all stakeholders if the rate limiting step in the drug discovery process can be solved.
Shifting perspectives on our WGS and lower sample numbers focus
Increasingly, we are seeing the genetic field slowly pivot toward the path we at GI have insisted on (and blazed) all along. Namely, 1) whole genome (WGS) instead of whole exome (WES) and 2) well characterized cohorts (which can mean smaller number of samples) instead of larger and larger studies.
Genetic data samples size: bigger is not better
Most genome analysis efforts are pursuing the “more data, bigger GWAS” strategy to solve the herculean causal gene discovery challenge. But this approach is infeasible on many levels. Rather, actionable disease genes can be identified using a small number of well-structured, well-defined samples.
Genetic data type: whole genome or whole exome?
The genomic industry has favored whole exome (WES) due to cost and analysis difficulties, but the secrets of the genome reside in the whole genome (WGS). Those who can innovate to solve the herculean WGS analysis challenge will unlock tremendous value for their stakeholders and society.
Genetic Intelligence awarded Competitive grant from the National Science Foundation
Genetic Intelligence has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $225,000 to conduct research and development (R&D) work on causal disease gene identification from Whole Genomes using Artificial Intelligence